Atorvastatin Inhibits Myocardial Apoptosis in a Swine Model of Coronary Microembolization by Regulating PTEN/PI3K/Akt Signaling Pathway

Cellular Physiology and Biochemistry

Volumn 38, Issue 1, 2016, Pages 207-219

  Wang, Jiangyou ^a   Chen, Han ^b   Zhou, You ^a   Su, Qiang ^a   Liu, Tao ^a   Wang, Xian Tao ^a   Li, Lang ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b WUHAN ASIA HEART HOSPITAL   (China)

Author keywords

Akt; Apoptosis; Atorvastatin; Coronary microembolization; PI3K; PTEN

Indexed keywords

ATORVASTATIN; CASPASE 3; MESSENGER RNA; MICROSPHERE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SMALL INTERFERING RNA; TROPONIN I;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ARTIFICIAL EMBOLISM; CARDIOVASCULAR PARAMETERS; CELL DEATH; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY MICROEMBOLIZATION; CORONARY SINUS; DOWN REGULATION; ECHOCARDIOGRAPHY; FRACTIONAL SHORTENING; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HISTOPATHOLOGY; IN VIVO STUDY; INFLAMMATORY CELL; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LEFT VENTRICLE END DIASTOLIC DIAMETER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUNEL ASSAY; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIAC MUSCLE; DISEASE MODEL; DRUG EFFECTS; EMBOLISM; GENETICS; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PIG; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; ATORVASTATIN CALCIUM; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ECHOCARDIOGRAPHY; EMBOLISM; MYOCARDIAL INFARCTION; MYOCARDIUM; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SWINE; TROPONIN I;

EID: 84955561182     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000438622     Document Type: Article

References (33)

1. Heusch G, Kleinbongard P, Bose D, Levkau B, Haude M, Schulz R, Erbel R: Coronary microembolization: From bedside to bench and back to bedside. Circulation 2009;120:1822-1836.
2. Dorge H, Schulz R, Belosjorow S, Post H, van de Sand A, Konietzka I, Frede S, Hartung T, Vinten-Johansen J, Youker KA, Entman ML, Erbel R, Heusch G: Coronary microembolization: The role of tnf-alpha in contractile dysfunction. J Mol Cell Cardiol 2002;34:51-62.
3. Zhang QY, Ge JB, Chen JZ, Zhu JH, Zhang LH, Lau CP, Tse HF: Mast cell contributes to cardiomyocyte apoptosis after coronary microembolization. J Histochem Cytochem 2006;54:515-523.
4. Dorge H, Neumann T, Behrends M, Skyschally A, Schulz R, Kasper C, Erbel R, Heusch G: Perfusioncontraction mismatch with coronary microvascular obstruction: Role of inflammation. Am J Physiol Heart Circ Physiol 2000;279:H2587-2592.
5. Thielmann M, Dorge H, Martin C, Belosjorow S, Schwanke U, van De Sand A, Konietzka I, Buchert A, Kruger A, Schulz R, Heusch G: Myocardial dysfunction with coronary microembolization: Signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. Circ Res 2002;90:807-813.
6. Wang J, Li L, Su Q, Zhou Y, Chen H, Ma G, Liu T, Tang Z, Liu Y: The involvement of phosphatase and tensin homolog deleted on chromosome ten (pten) in the regulation of inflammation following coronary microembolization. Cell Physiol Biochem 2014;33:1963-1974.
7. Su Q, Li L, Zhou Y, Wang J, Liu Y, Ma G: Induction of myocardial pdcd4 in coronary microembolizationrelated cardiac dysfunction: Evidence from a large-animal study. Cell Physiol Biochem 2014;34:533-542.
8. Qiu R, Cai A, Dong Y, Zhou Y, Yu D, Huang Y, Zheng D, Rao S, Feng Y, Mai W: Sdf-1alpha upregulation by atorvastatin in rats with acute myocardial infarction via nitric oxide production confers anti-inflammatory and anti-apoptotic effects. J Biomed Sci 2012;19:99.
9. Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von Birgelen C, Haude M, Heusch G, Erbel R: Preprocedural statin medication reduces the extent of periprocedural non-q-wave myocardial infarction. Circulation 2002;106:2180-2183.
10. Li L, Su Q, Wang Y, Dai R, Lu Y, Su B, Zhao Y: Effect of atorvastatin (lipitor) on myocardial apoptosis and caspase-8 activation following coronary microembolization. Cell Biochem Biophys 2011;61:399-406.
11. Latronico MV, Costinean S, Lavitrano ML, Peschle C, Condorelli G: Regulation of cell size and contractile function by akt in cardiomyocytes. Ann N Y Acad Sci 2004;1015:250-260.
12. Oudit GY, Penninger JM: Cardiac regulation by phosphoinositide 3-kinases and pten. Cardiovasc Res 2009;82:250-260.
13. Breuckmann F, Nassenstein K, Bucher C, Konietzka I, Kaiser G, Konorza T, Naber C, Skyschally A, Gres P, Heusch G, Erbel R, Barkhausen J: Systematic analysis of functional and structural changes after coronary microembolization: A cardiac magnetic resonance imaging study. JACC Cardiovasc Imaging 2009;2:121-130.
14. Carlsson M, Wilson M, Martin AJ, Saeed M: Myocardial microinfarction after coronary microembolization in swine: Mr imaging characterization. Radiology 2009;250:703-713.
15. Yamada KM, Araki M: Tumor suppressor pten: Modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 2001;114:2375-2382.
16. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH: The role of phosphoinositide-3 kinase and pten in cardiovascular physiology and disease. J Mol Cell Cardiol 2004;37:449-471.
17. De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N: The ras/raf/mek/erk and the pi3k/akt signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16:S17-27.
18. Aksamitiene E, Kiyatkin A, Kholodenko BN: Cross-talk between mitogenic ras/mapk and survival pi3k/akt pathways: A fine balance. Biochem Soc Trans 2012;40:139-146.
19. Torella D, Rota M, Nurzynska D, Musso E, Monsen A, Shiraishi I, Zias E, Walsh K, Rosenzweig A, Sussman MA, Urbanek K, Nadal-Ginard B, Kajstura J, Anversa P, Leri A: Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ Res 2004;94:514-524.
20. Wang Z, Zhang H, Xu X, Shi H, Yu X, Wang X, Yan Y, Fu X, Hu H, Li X, Xiao J: Bfgf inhibits er stress induced by ischemic oxidative injury via activation of the pi3k/akt and erk1/2 pathways. Toxicol Lett 2012;212:137-146.
21. Ye Z, Guo Q, Xia P, Wang N, Wang E, Yuan Y: Sevoflurane postconditioning involves an up-regulation of hif-1alpha and ho-1 expression via pi3k/akt pathway in a rat model of focal cerebral ischemia. Brain Res 2012;1463:63-74.
22. Muslin AJ: Akt2: A critical regulator of cardiomyocyte survival and metabolism. Pediatr Cardiol 2011;32:317-322.
23. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, Hirsch E, Suzuki A, Shioi T, Irie-Sasaki J, Sah R, Cheng HY, Rybin VO, Lembo G, Fratta L, Oliveira-dos-Santos AJ, Benovic JL, Kahn CR, Izumo S, Steinberg SF, Wymann MP, Backx PH, Penninger JM: Regulation of myocardial contractility and cell size by distinct pi3k-pten signaling pathways. Cell 2002;110:737-749.
24. Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, Schulz R, Heusch G: Ischemic postconditioning in pigs: No causal role for risk activation. Circ Res 2009;104:15-18.
25. Tong H, Chen W, Steenbergen C, Murphy E: Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase c. Circ Res 2000;87:309-315.
26. Mocanu MM, Bell RM, Yellon DM: Pi3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol 2002;34:661-668.
27. Bi XY, He X, Zhao M, Yu XJ, Zang WJ: Role of endothelial nitric oxide synthase and vagal activity in the endothelial protection of atorvastatin in ischemia/reperfusion injury. J Cardiovasc Pharmacol 2013;61:391-400.
28. Li Y, Li J, Cui L, Lai Y, Yao Y, Zhang Y, Pang X, Wang J, Liu X: Inhibitory effect of atorvastatin on age-induced hcaec apoptosis by upregulating hsf-1 protein. Int J Biol Macromol 2013;57:259-264.
29. Tang XL, Sanganalmath SK, Sato H, Bi Q, Hunt G, Vincent RJ, Peng Y, Shirk G, Dawn B, Bolli R: Atorvastatin therapy during the peri-infarct period attenuates left ventricular dysfunction and remodeling after myocardial infarction. PLoS One 2011;6:e25320.
30. Haylor JL, Harris KP, Nicholson ML, Waller HL, Huang Q, Yang B: Atorvastatin improving renal ischemia reperfusion injury via direct inhibition of active caspase-3 in rats. Exp Biol Med (Maywood) 2011;236:755-763.
31. Miraglia E, Hogberg J, Stenius U: Statins exhibit anticancer effects through modifications of the pakt signaling pathway. Int J Oncol 2012;40:867-875.
32. Wu XL, Yang DY, Tan DJ, Yao HC, Chai W, Peng L: Inhibitory effect of atorvastatin on the cell growth of cardiac myxomas via the pten and phlpp2 phosphatase signaling pathway. Oncol Rep 2013;30:757-762.
33. Mensah K, Mocanu MM, Yellon DM: Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: A potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 2005;45:1287-1291.